Skip to main content

Table 2 Characteristics of Syrian patients with diabetes and hypertension, Shatila primary care clinic, Beirut, Lebanon, 2013–2017

From: Treating Syrian refugees with diabetes and hypertension in Shatila refugee camp, Lebanon: Médecins Sans Frontières model of care and treatment outcomes

Characteristics at first visit

DM-1 Only (n = 204)

DM-2 Only (n = 780)

HTN Only (n = 780)

DM + HTN (n = 880)

All patients (N = 2644)

Age - year (median, IQR)

22 (12–32)

51 (44–58)

54 (47–62)

57 (51–63)

53 (45–61)

Age categories - year - n (%)

     

 <18 y

75 (36)

1 (< 1)

2 (< 1)

0 (0)

78 (3)

 > = 18- < 40 y

112 (55)

113 (14)

79 (10)

36 (4)

340 (13)

 > = 40- < 60y

16 (8)

506 (65)

454 (58)

513 (58)

1489 (56)

 > = 60 y

1 (< 1)

160 (20)

245 (31)

331 (38)

737 (28)

Gender - n (%)

     

 Female

88 (43)

459 (59)

534 (68)

585 (66)

1666 (63)

 Male

116 (57)

321 (41)

246 (32)

295 (34)

978 (37)

Place of residency - n (%)

     

 In catchment area

55 (28)

218 (29)

271 (36)

221 (26)

765 (30)

 Outside catchment area

143 (72)

539 (71)

484 (64)

623 (74)

1789 (70)

Previously diagnosed - n (%)

     

 Yes

199 (98)

733 (94)

760 (97)

874 (99)

2566 (97)

 No - newly diagnosed

5 (2)

47 (6)

20 (3)

6 (<1)

78 (3)

Cardiovascular co-morbiditya

     

 Yes

2 (< 1)

75 (10)

158 (20)

140 (16)

375 (14)

 No

202 (99)

705 (90)

622 (80)

740 (84)

2269 (86)

 HbA1C - % [mean (SD)]

9.9 (2.1)

8.9 (2.1)

NA

8.7 (2.0)

9.0 (2.1)

Blood pressureb - mmHg [(mean (SD)]

     

 Systolic blood pressure

NA

NA

142 (25)

139 (22.4)

141 (23.7)

 Diastolic blood pressure

NA

NA

87 (14.4)

84 (12.8)

86 (13.7)

Number of prescribed medicationsb

     

 1

NA

NA

249 (33)

335 (40)

584 (36)

 2

NA

NA

321 (42)

332 (40)

653 (41)

 > = 3

NA

NA

193 (25)

168 (20)

361 (23)

Insulin usec

     

 Yes

204 (100)

73 (9)

NA

117 (13)

394 (21)

 No

0 (0)

705 (91)

NA

751 (87)

1456 (79)

Characteristics at last visit

     

Number of prescribed medicationsb

     

 1

NA

NA

167 (22)

219 (26)

386 (24)

 2

NA

NA

296 (39)

325 (38)

621 (38)

 > = 3

NA

NA

300 (39)

310 (36)

610 (38)

Insulin usec

     

 Yes

204 (100)

141 (18)

NA

190 (22)

535 (29)

 No

0 (0)

639 (82)

NA

690 (78)

1329 (71)

 Follow-up period while in the program - months (median, IQR)

14 (6–23)

11 (4–19)

13 (5–25)

16 (6–26)

13 (5–24)

 Lost to follow-up - n (%)

18 (9)

133 (17)

136 (17)

139 (16)

426 (16)

  1. DM-1 type-1 diabetes, DM-2 type-2 diabetes, HTN hypertension, IQR interquartile range, NA not applicable, SD standard deviation
  2. aCardiovascular co-morbidity is defined as one of the following: ischemic heart disease, heart failure, transient ischemic attack, cerebrovascular accident, or peripheral arterial disease
  3. bCalculated for patients with hypertension; 43 patients (2.6%) had this data missing in their files and were excluded from the calculation
  4. cCalculated for patients with diabetes